Skip to content
Scottsdale PRP Field Notes
The evidence changes when the body part changes

Scottsdale PRP Field Notes

Common platelet-rich plasma, or PRP, questions have direct answers

Soreness often raises questions after home care stops helping

A knee may still ache on stairs, or a heel may hurt each morning. People then ask what PRP is, whether it helps that area and who pays.

PRP is the shortened name for platelet-rich plasma; your blood is spun so its platelet-rich portion can be saved. The questions below cover each sore area, cost and the visit.

Online answers can’t examine a joint or tendon. Heat, fever or sudden weakness requires quick care.

What does PRP mean, and how is it made?

PRP means platelet-rich plasma. The clinician takes blood from you, uses a fast-spinning machine to divide it and saves the platelet-rich portion for the painful place.

Do all machines prepare PRP the same way?

No, each machine may keep a different mix of platelets and white blood cells. Ask what the clinic prepares and why that mix suits the painful area.

Does PRP work for tennis elbow?

One study found no added gain at twelve weeks, but elbow comfort and use improved more by twenty-four weeks. An exam must still confirm that the tendon causes your soreness.

Does PRP work for plantar fasciitis, the sore band under the heel?

Studies favor PRP over a steroid shot from about three to six months for lasting heel soreness. It can’t replace stretching, shorter walks or an exam for another cause.

Does PRP work for knee arthritis?

Knee findings conflict: PRP didn’t beat sterile salt water in one study, but other studies favored it over gel shots. The exam and X-ray help set a realistic walking goal.

Does PRP work for the shoulder or rotator cuff?

Shoulder findings are mixed because studies cover different injuries and care during surgery. The exam must identify the sore tissue before those findings apply to you.

Where is the Scottsdale PRP office?

The listed office is on East Mountain View Road. Drivers from farther north may use Pima Road or Loop 101, but current directions need checking before departure.

Does insurance cover PRP in Arizona?

Most people pay the full clinic bill themselves for joint or tendon PRP; they don’t have to bring paper cash. Ask the health plan and clinic to confirm current coverage.

Sources

  1. A clinical-recommendations review graded PRP indication by indication: good evidence for leukocyte-poor PRP in knee osteoarthritis; moderate-to-high-quality evidence for leukocyte-rich PRP in patellar tendinopathy and for PRP in plantar fasciitis; INSUFFICIENT evidence to routinely recommend PRP for rotator cuff tendinopathy, hip osteoarthritis or high ankle sprains; and demonstrated LACK of efficacy for Achilles tendinopathy, muscle injuries, acute fracture or non-union, and as a surgical augment in rotator cuff repair, Achilles repair and ACL reconstruction.

    Le ADK, Enweze L, DeBaun MR, et al. — Current Clinical Recommendations for Use of Platelet-Rich Plasma. Current Reviews in Musculoskeletal Medicine, 2018. DOI: 10.1007/s12178-018-9527-7.

  2. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

    Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

  3. A meta-analysis of 18 Level I randomized trials (811 patients receiving PRP, 797 receiving hyaluronic acid, mean follow-up 11.1 months) found mean improvement in total WOMAC scores was significantly higher with PRP (44.7%) than with hyaluronic acid (12.6%) (P<.01), and 6 of 11 VAS-reporting studies found significantly less pain with PRP at latest follow-up.

    Belk JW, Kraeutler MJ, Houck DA, et al. — Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. American Journal of Sports Medicine, 2021. DOI: 10.1177/0363546520909397.

  4. A 12-centre randomized controlled trial of 230 patients with chronic lateral epicondylar tendinopathy compared tendon needling with leukocyte-enriched PRP against tendon needling alone. At 12 weeks there was no significant difference (55.1% versus 47.4% pain improvement; P=.163). At 24 weeks the PRP group reported 71.5% versus 56.1% pain improvement (P=.019), a 83.9% versus 68.3% success rate (P=.037), and significantly less residual elbow tenderness (29.1% versus 54.0%; P=.009). No significant complications occurred in either group.

    Mishra AK, Skrepnik NV, Edwards SG, et al. — Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. American Journal of Sports Medicine, 2014. DOI: 10.1177/0363546513494359.

  5. A systematic review and meta-analysis of nine randomized trials (239 PRP patients, 240 corticosteroid patients) in chronic plantar fasciitis found statistically significant differences in VAS pain favouring PRP at 1-1.5, 3, 6 and 12 months, and in AOFAS function favouring PRP at 6 and 12 months (no difference at 1 and 3 months).

    Hurley ET, Shimozono Y, Hannon CP, et al. — Platelet-Rich Plasma Versus Corticosteroids for Plantar Fasciitis: A Systematic Review of Randomized Controlled Trials. Orthopaedic Journal of Sports Medicine, 2020. DOI: 10.1177/2325967120915704.

  6. In a double-blind, placebo-controlled trial of 54 patients with chronic midportion Achilles tendinopathy, all doing eccentric exercises, VISA-A scores improved 21.7 points with PRP and 20.5 points with saline over 24 weeks - an adjusted between-group difference of -0.9 (95% CI -12.4 to 10.6), excluding the predefined relevant difference of 12 points. PRP added nothing to eccentric loading.

    de Vos RJ, Weir A, van Schie HT, et al. — Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA, 2010. DOI: 10.1001/jama.2009.1986.

  7. An updated meta-analysis of six randomized trials (422 patients) found no benefit of PRP over placebo for Achilles tendinopathy on VISA-A at 3 months (mean difference 1.7; 95% CI -1.8 to 5.2), 6 months (0.5; 95% CI -8.5 to 9.3) or 1 year (-7.9; 95% CI -27.3 to 11.6), nor on VAS pain at 3 months. Funnel-plot asymmetry suggested publication bias inflating apparent benefits. The authors wrote that PRP should not be used to treat Achilles tendinopathy until high-quality trials show a clear clinical benefit.

    Barreto ESR, Antunes Junior CR, Silva IC, et al. — Is Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials. Clinical Orthopaedics and Related Research, 2025. DOI: 10.1097/CORR.0000000000003349.

  8. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

    U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.

  9. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

    Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

  10. The Cochrane review of platelet-rich therapies for musculoskeletal soft-tissue injuries concluded there is currently insufficient evidence to support the use of platelet-rich therapy for treating musculoskeletal soft tissue injuries, overall and for individual conditions - including pooled data from six trials of PRP applied during rotator cuff repair surgery, which showed no statistically or clinically significant long-term functional difference. The review ended with an explicit call for standardisation of PRP preparation methods.

    Moraes VY, Lenza M, Tamaoki MJ, et al. — Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database of Systematic Reviews, 2014. DOI: 10.1002/14651858.CD010071.pub3.

  11. A meta-analysis of six randomized trials (211 PRP patients, 197 hyaluronic acid patients, mean follow-up about 12 months) in hip osteoarthritis found NO significant difference between PRP and hyaluronic acid in weighted improvement on WOMAC, VAS or Harris Hip Score - including in a subanalysis isolating leukocyte-poor PRP.

    Belk JW, Houck DA, Littlefield CP, et al. — Platelet-Rich Plasma Versus Hyaluronic Acid for Hip Osteoarthritis Yields Similarly Beneficial Short-Term Clinical Outcomes: A Systematic Review and Meta-analysis of Level I and II Randomized Controlled Trials. Arthroscopy, 2022. DOI: 10.1016/j.arthro.2021.11.005.

  12. A multicentre, double-blinded, placebo-controlled trial randomised 100 patients with ankle (tibiotalar) osteoarthritis to two ultrasound-guided intra-articular injections of PRP or placebo. Symptom scores improved by 10 points with PRP and 11 points with placebo, an adjusted between-group difference over 26 weeks of -1 (95% CI -6 to 3; P=.56). The authors concluded the results do not support the use of PRP injections for ankle osteoarthritis.

    Paget LDA, Reurink G, de Vos RJ, et al. — Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.16602.

An exam comes before a treatment choice

At its Scottsdale office, QC Kinetix medical providers—clinicians who examine you—offer PRP, a non-surgical regenerative treatment made by drawing, spinning and concentrating your blood.

Book a free consultation